SCHEMBL20487495

SCHEMBL20487495

COC(=O)c1ccc(N)c(C#Cc2ccc(C)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 6/20 0.51
MAPT P10636 5/20 0.51
HPGD P15428 5/20 0.51
HSD17B10 Q99714 2/20 0.51
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
GAA P10253 2/20 0.48
GLA P06280 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
ATM Q13315 1/20 0.48
PTPN11 Q06124 1/20 0.45
USP2 O75604 1/20 0.42
CYP2C9 P11712 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20487128 0.93 MAPT (0.51) TDP1ALDH1A1KDM4EMAPTHPGD
SCHEMBL20488212 0.88 CA1 (0.53) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL23252136 0.87 ALDH1A1 (0.49) TDP1ALDH1A1KDM4EMAPTHPGD
SCHEMBL20487124 0.86 MAPT (0.46) TDP1ALDH1A1KDM4EMAPTHPGD
SCHEMBL20488208 0.85 HPGD (0.44) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL20487479 0.84 HDAC1 (0.60) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL20487893 0.84 CASP3 (0.56) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL2802065 0.83 TDP1 (0.51) TDP1ALDH1A1KDM4EMAPTHPGD
SCHEMBL1138907 0.82 ABL1 (0.49) TDP1ALDH1A1KDM4EMAPTHPGD
SCHEMBL16140276 0.82 TDP1 (0.77) TDP1ALDH1A1MAPTHPGDPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-01 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
WO-2018160967-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 TDP1 2053/4885ALDH1A1 3459/4885KDM4E 978/4885
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase MELK, HIPK1, HIPK3 TDP1 2175/4885ALDH1A1 2911/4885KDM4E 1151/4885
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 TDP1 2053/4885ALDH1A1 3459/4885KDM4E 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.